Source:http://linkedlifedata.com/resource/pubmed/id/12448863
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2002-11-25
|
pubmed:abstractText |
Facing financial pressures, the provinces and territories have chosen to use "cost-effectiveness" for making decisions about drug listings. This study examines the scientific basis for the procedures used to determine cost-effectiveness in 5 Canadian provinces.
|
pubmed:language |
eng
|
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:author | |
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
421-5
|
pubmed:dateRevised |
2008-2-13
|
pubmed:articleTitle |
"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.
|
pubmed:affiliation |
Division of Community Health, Memorial University of Newfoundland, Health Sciences Centre, St. John's, NF A1B 3V6. roywest@mun.ca
|